Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Titel:
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Auteur:
Dimopoulos, Meletios A Goldschmidt, Hartmut Niesvizky, Ruben Joshua, Douglas Chng, Wee-Joo Oriol, Albert Orlowski, Robert Z Ludwig, Heinz Facon, Thierry Hajek, Roman Weisel, Katja Hungria, Vania Minuk, Leonard Feng, Shibao Zahlten-Kumeli, Anita Kimball, Amy S Moreau, Philippe